Product comprising a transduction inhibitor of heterotrimeric g protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer

Abstract

A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one other anti-cancer agent selected from the group consisting of prenyltransferase inhibitors, taxol and its analogues, gemcitabine and camptothecin and its analogues, administered simultaneously, separately or spread over a period of time and a pharmaceutical carrier.

1 . A composition for treating cancer comprising an antitumorally effective amount of a product comprising:
 a pharmaceutically acceptable carrier,   at least one transduction inhibitor of heterotrimeric G protein signals selected from the group consisting of 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine: 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine; mixtures thereof; and pharmaceutically acceptable salts thereof; and   at least one other anti-cancer agent selected from the group consisting of 1-(2-(1-((4-cyano)phenylmethyl)imidazol-4-yl)1-oxoethyl-2,5-dihydro-4-(2-methoxyphenyl)imidazo[1,2c][1,4]benzodiazetpine, 4-(2-bromophenyl)-1-(2-(1-((4-cyano-3-methoxy)phenylmethyl)-imidazo-5-yl-1-oxoethyl)-1,2-dihydro-8-fluoro-imidazo[1,2a][1,4]-benzodiazepine, (±) 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-amino-(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)quinolinone; taxol; gemcitabine; mixtures thereof; and pharmaceutically acceptable salts thereof;   wherein the composition is administered simultaneously, separately or spread over a period of time.   
   
   
       2 .- 10 . (canceled) 
   
   
       11 . A method of treating cancer in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antitumorally effective amount of a composition of  claim 1 . 
   
   
       12 . The composition of  claim 1 , wherein the transduction inhibitor of heterotrimeric G protein signals is 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine and the anti-cancer agent is taxol. 
   
   
       13 . The composition of  claim 1 , wherein the transduction inhibitor of heterotrimeric G protein signals is 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine and the anti-cancer agent is gemcitabine. 
   
   
       14 . The composition of  claim 1 , wherein the transduction inhibitor of heterotrimeric G protein signals is 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine and the anti-cancer agent is (+)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)-amino-( 1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)quinolinone. 
   
   
       15 . The composition of  claim 1 , wherein the transduction inhibitor of heterotrimeric G protein signals is 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine and the other anti-cancer agent is 4-(2-bromophenyl)-1-(2-(1-((4-cyano-3-methoxy)phenylmethyl)-imidazo-5-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-imidazo[1,2a][1,4]-benzodiazepine. 
   
   
       16 . The composition of  claim 1 , wherein the transduction inhibitor of heterotrimeric G protein signals is 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine and the anti-cancer agent is 1-(2-(1-((4-cyano)phenylmethyl)imidazol-4-yl)-1-oxoethyl-2,5-dihydro-4-(2-methoxyphenyl)imidazo [1,2c][1,4]benzodiazepine.